Prognostic and predictive value of c-erbB-2 (HER-2/neu) gene amplification in human breast cancer

Breast Cancer

Volumn 8, Issue 1, 2001, Pages 38-44

  Tsuda, Hitoshi ^a,b  

^a National Cancer Center   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Breast cancer; C erbB 2 (HER 2 neu); FISH; Gene amplification; Immunohistochemistry; Predictive factor; Prognostic factor; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

BREAST TUMOR; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FEMALE; GENE AMPLIFICATION; GENETICS; HUMAN; METABOLISM; METASTASIS; PROGNOSIS; PROTO ONCOGENE; REVIEW; SURVIVAL RATE;

BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM METASTASIS; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0035227887     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02967476     Document Type: Review

References (46)

1. Schechter AL, Hung MC, Vaidyanathan L, et al: The neu gene: An erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 229:976-978, 1985. (Pubitemid 16248489)
2. Bergmann CI, Hung MC, Weinberg RA: The neu oncogene encodes an epidermal growth factor receptor- related protein. Nature 319:226-230, 1986. (Pubitemid 16128785)
3. Yamamoto T, Ikawa S, Akiyama T, et al: Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319:230-234, 1986. (Pubitemid 16128786)
4. Akiyama T, Sudo C, Ogawara H, et al: The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644-1646, 1986. (Pubitemid 16095607)
5. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987. (Pubitemid 17231334)
6. Clark GM, McGuire WL: Follow-up study of HER- 2/neu amplification in primary breast cancer. Cancer Res 51:944-948, 1991.
7. Yokota J, Yamamoto T, Toyoshima K, et al: Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1:765-767, 1986.
8. Tsuda H, Hirohashi S, Shimosato Y, et al: Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res 49:3104-3108, 1989. (Pubitemid 19148652)
9. Tsuda H, Sakamaki C, Tsugane S, et al: A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases. Breast Cancer Res Treat 48:21-32, 1998. (Pubitemid 28073530)
10. Kallioniemi OP, Kallioniemi A, Kurisu W, et al: ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 89:5321-5325, 1992.
11. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989. (Pubitemid 19147683)
12. Wright C, Angus B, Nicholson S, et al: Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res 49:2087-2090, 1989. (Pubitemid 19106519)
13. Tsuda H, Hirohashi S, Shimosato Y, et al: Immunohistochemical study on overexpression of c-erbB-2 protein in human breast cancer: Its correlation with gene amplification and long-term survival of patients. Jpn J Cancer Res 81:327-332, 1990. (Pubitemid 20180590)
14. Jacobs TW, Gown AM, Yaziji H, et al: Specificity of HercepTest in Determining HER-2/neu Status of Breast Cancers Using the United States Food and Drug Administration-Approved Scoring System. J Clin Oncol17:1983-1987, 1999. (Pubitemid 29318825)
15. Muss HB, Thor AD, Berry DA, et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330: 1260-1266, 1994; ibid 331:211, 1994.
16. Paik S, Bryant J, Park C, et al: erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90:1361-1370, 1998. (Pubitemid 28439960)
17. Thor AD, Berry DA, Budman DR, et al: erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90:1346-1360, 1998. (Pubitemid 28439959)
18. Newby JC, Johnston SR, Smith IE, et al: Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 3:1643-1651, 1997. (Pubitemid 27431575)
19. Leitzel K, Teramoto Y, Konrad K, et al: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol13:1129-1135, 1995.
20. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol17:2639-2648, 1999. (Pubitemid 29415219)
21. Shak S for the Herceptin Multinational Investigator Study Group: Overview of the trastuzumab (herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Semin Oncol26 (suppl 12):71-77, 1999.
22. Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol26(Suppl 12):78-83, 1999. (Pubitemid 29411436)
23. Vogel C, Cobleigh M, Tripathy D, et al: First line, non-hormonal, treatment of women with HER2 overexpressing metastatic breast cancer with herceptin (trastuzumab, humanized anti-HER2 antibody). Proc Am Soc Clin Oncol 18:71a, 2000. (Abstract)
24. Mass RD, Sanders C, Charlene K, et al: The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the herceptin pivotal trials. Proc Am Soc Clin Oncol 18: 75a, 2000. (Abstract)
25. McNeil C: Using HER2 to choose chemotherapy in breast cancer: Is it ready for the clinic? J Natl Cancer Inst 91:110-112, 1999.
26. Roche PC, Ingle JN: Increased HER2 with U.S. Food and Drug Administration-approved antibody. J Clin Oncol17:434, 1999. (Pubitemid 29022424)
27. Maia DM: Immunohistochemical assays for HER2 overexpression. J Clin Oncol17:1650, 1999.
28. Berger MS, Locher GW, Saurer S, et al: Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48:1238-1243, 1988. (Pubitemid 18075540)
29. Tsuda H, Hirohashi S, Shimosato Y, et al: Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. A retrospective analysis of 176 cases. Cancer 65:1794-1800, 1990. (Pubitemid 20116652)
30. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11:359-377, 1957.
31. Elston CW: Grading of invasive carcinoma of the breast. In: Page DL, Anderson TV, eds, Diagnostic Histopathology of the Breast, Churchill Livingstone, New York, pp300-311, 1987.
32. Frierson HF Jr, Wilbur DC, Gaffey MJ, et al: Quantitative image cytometry of infiltrating ductal carcinoma: Comparison with prognostic parameters and reproducibility of histological grade. Hum Pathol 27: 821-826, 1996. (Pubitemid 26287225)
33. Ali IU, Lidereau R, Theillet C, et al: Reduction to homozygosity of genes on chromosome 11 in human breast neoplasia. Science 238: 185-188, 1987. (Pubitemid 17139718)
34. Bieche I, Champ6me MH, Matifas F, et al: Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer. Lancet 339:139-143, 1992.
35. van de Vijver MJ, Peterse JL, Mooi WJ, et al: Neu-prorein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage I! breast cancer. N Engl J Med 319:1239-1245, 1988. (Pubitemid 18267063)
36. Tsuda H, Fukutomi T, Hirohashi S: Pattern of gene alterations in intraductal breast neoplasms associated with histological type and grade. Clin Cancer Res 1: 261-267, 1995.
37. Baird RM, Worth A, Hislop G: Recurrence after lumpectomy for comedo-type intraductal carcinoma of the breast. Am J Surg 159:479-481, 1990. (Pubitemid 20161004)
38. Solin LJ, Yeh IT, Kurtz J, et al: Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation. Correlation of pathologic parameters with outcome of treatment. Cancer 71:2532-2542, 1993. (Pubitemid 23100488)
39. Tsuda H, Hirohashi S: Multiple developmental pathways of highly aggressive breast cancers disclosed by comparison of histological grades and c-erbB-2 expression patterns in both the non-invasive and invasive portions. Pathol Int 48:518-525, 1998. (Pubitemid 28341088)
40. Shimizu C, Fukutomi T, Tsuda H, et al: C-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol73:17-20, 2000. (Pubitemid 30067528)
41. Prost S, Le MG, Douc-Rasy S, et al: Association of cerbB- 2 gene amplification with poor prognosis in noninflammatory breast carcinomas but not in carcinomas of the inflammatory type. Int J Cancer 58:763-768, 1994. (Pubitemid 24306360)
42. Lammie GA, Barnes DM, Millis RR, et al: An immunohistochemical study of the presence of cerbB- 2 protein in Paget's disease of the nipple. Histopathology 15:505-514, 1989. (Pubitemid 19272725)
43. Sugano S, Mukai K, Tsuda H, et al: Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: An indicator of aggressiveness. Laryngoscope 102:923-927, 1992.
44. Uchino S, Tsuda H, Maruyama K, et al: Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer 72: 3179-3184, 1993. (Pubitemid 23356757)
45. Kihana T, Tsuda H, Teshima S, et al: Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. Cancer 73:148-153, 1994. (Pubitemid 24012735)
46. Hasebe T, Mukai K, Yamaguchi N, et al: Prognostic value of immunohistochemical staining for proliferating cell nuclear antigen, p53, and c-erbB-2 in sebaceous gland carcinoma and sweat gland carcinoma: Comparison with histopathological parameter. Mod Pathol 7:37-43, 1994.